In light of the ongoing coronavirus disease (COVID-19) pandemic, PEPperPRINT has rapidly developed and produced a new peptide microarray based on the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral genome. Derived from the virus isolate sequence under GenBank ID: MN908947.3 (including 49 mutations of the B.1.1.7, 501.V2, B.1.1.28 and P.1 Manaus variants), the PEPperCHIP® SARS-CoV-2 Proteome Microarray gives researchers access to serologically screen 4,932 individual peptides spanning the entire viral proteome.
Identify, profile, and compare specific IgG, IgA, and IgM antibody responses in patient or animal sera for vaccine development, or screen viral antigens to find and characterize immunodominant epitopes for in-vitro diagnostics research.
Fig.1. Proposed antibody fingerprinting workflow using the PEPperCHIP® SARS-CoV-2 Proteome Microarray. The entire SARS-CoV-2 viral proteome is translated into overlapping peptides and printed onto glass slides. Patient sera is incubated on the chip and antibodies present in the sample bind to epitopes recognized within individual peptides. The resulting response profile may be compared across different samples to monitor B-cell responses over time, or to determine immunodominant epitopes that may be further validated as potential disease-specific biomarkers for IVD development.
Case Study: In collaboration with the Institute of Virology of the Charité, we have screened COVID-19 patient sera in comparison with healthy controls using our PEPperCHIP® SARS-CoV-2 Proteome Microarray. See the first results of the study and the scientific poster with our findings in the links below:
|Epitope Signatures in COVID-19 Patients with Mild and Severe Disease Outcome|
The PEPperCHIP® SARS-CoV-2 Proteome Microarray chip contains a single peptide array and is compatible with a 3/1 well PEPperCHIP® Incubation Tray. Each chip produced comes with HA and polio assay control peptide spots.
SARS-CoV-2 proteome-wide analysis revealed significant epitope signatures in COVID-19 patients.
Tatjana Schwarz, Kirsten Heiss, Yuvaraj Mahendran, Fiordiligie Casilag, Florian Kurth, Leif Sander, Clemens-Martin Wendtner, Manuela A. Hoechstetter, Marcel A. Müller, Renate Sekul, Christian Drosten, Volker Stadler and Victor M. Corman. Front. Immunol. [https://www.frontiersin.org/articles/10.3389/fimmu.2021.629185/abstract]
SARS-CoV-2 Spike Protein Arrested in the Closed State Induces Potent Neutralizing Responses.
George W. Carnell, Katarzyna A. Ciazynska, David A. Wells, Xiaoli Xiong, Ernest T. Aguinam, Stephen H. McLaughlin, Donna Mallery. Preprint. Immunology, 14. January 2021. [doi.org/10.1101/2021.01.14.426695]
SARS-CoV-2 Epitope Mapping on Microarrays Highlights Strong Immune-Response to N Protein Region.
Angelo Musicò, Roberto Frigerio, Alessandro Mussida, Luisa Barzon, Alessandro Sinigaglia, Silvia Riccetti, Federico Gobbi. Vaccines 9, Nr. 1 (11. January 2021): 35. [doi.org/10.3390/vaccines9010035]
Recent Advances in the Diagnosis of COVID-19: A Bird’s Eye View.
Bhawna Sharma, Mohd FardeenHusain Shahanshah, Sanjay Gupta, and Vandana Gupta. Expert Review of Molecular Diagnostics, 10. January 2021, 14737159.2021.1874354. [doi.org/10.1080/14737159.2021.1874354]
Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.
Yan Lu, Yajun Wang, Zhen Zhang, Jingliang Huang, Meicun Yao, Guobin Huang, Yuanyuan Ge, et al. Published by Juraj Ivanyi. Journal of Immunology Research 2020 (16. October 2020): 1–8. [doi.org/10.1155/2020/9465398]
Rapid Response to Pandemic Threats: Immunogenic Epitope Detection of Pandemic Pathogens for Diagnostics and Vaccine Development Using Peptide Microarrays.
Kirsten Heiss, Jasmin Heidepriem, Nico Fischer, Laura K Weber, Christine Dahlke, Thomas Jaenisch, und Felix F Loeffler. Journal of Proteome Research, 5. September 2020 [doi.org/10.1021/acs.jproteome.0c00484]
Molecular and Serological Tests for COVID-19. A Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics.
Kubina, Robert, und Arkadiusz Dziedzic. Diagnostics 10, Nr. 6 (26. June 2020): 434. [doi.org/10.3390/diagnostics10060434]
Distinct Early IgA Profile May Determine Severity of COVID-19 Symptoms: An Immunological Case Series.
Dahlke, Christine, Jasmin Heidepriem, Robin Kobbe, Rene Santer, Till Koch, Anahita Fathi, My L. Ly, et al. Preprint. Infectious Diseases (except HIV/AIDS), April 17, 2020 [doi.org/10.1101/2020.04.14.20059733]